Douglas B. Johnson, MD, MSCI, offers a comprehensive exploration of the nuances for using neoadjuvant therapy, addressing various treatment combinations, along with recommendations for first-line systemic therapy.
June 02, 2024
Recent approvals herald novel strategies for addressing advanced or metastatic breast cancer with ESR1 mutations.
In certain patients, surgical omission, radiotherapy omission, and immunotherapy are being explored.
In general, mutations can occur in several genes in cytologically normal AML cells, including NPM1, FLT3, CEBPA, MLL, NRAS.
Health care organizations face a growing wave of cyberattacks and must implement strong defenses to protect patient data and ensure operational continuity.
The debate on non-specific vs targeted therapies in oncology highlights the need for a balanced approach optimizing existing agents while developing biomarkers and precision medicine.
Recent data, trials, approvals, and presentations during the 2024 American Urological Association Annual Meeting paint a positive treatment landscape for patients with metastatic and non–muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
